PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient

Abstract

Background: Androgen-independent prostate cancer (AIPCA) is a difficult disease to treat. Fulvestrant has shown activity inhibiting estrogen receptor dimerization, and the androgen receptor has been shown to stimulate growth in prostate cancer cell lines.

Case report: A 79-year-old metastatic prostate cancer patient with AIPCA was treated with fulvestrant acetate with a loading dose strategy. Without recording any significant side effects, the prostate-specific antigen (PSA) level decreased from 154 ng/ml to 0.45 ng/ml 8 weeks after the first treatment administration.

Conclusion: Fulvestrant was able to reduce the PSA level in this AIPC patient without any toxicity.